Evidence map›Paper›PMID 33495229›Full record

ArticleAntimicrobial agents and chemotherapy2021

Daisuke Oka, Naomitsu Yamaya, Takuya Kuno, Yuta Asakawa, Toshiyuki Shiragiku, Liang Chen, Jingbo Xue, Abudusaimi Mamuti, Fangguo Ye, Jiangqin Sun and 6 more

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Review
  3. The Urgent Threat ofBiomedicines · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Daisuke OkaDepartment of Medical Innovations, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan Oka.Disuke@otsuka.jp Inagaki.Katsuya@otsuka.jp.
Naomitsu YamayaDepartment of Drug Metabolism and Pharmacokinetics, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
Takuya KunoDepartment of Drug Metabolism and Pharmacokinetics, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
Yuta AsakawaDepartment of Investigative Toxicology, Nonclinical Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
Toshiyuki ShiragikuDepartment of Drug Safety Research, Nonclinical Research Center, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
Liang ChenOtsuka Shanghai Research Institute, Shanghai, China.
Jingbo XueOtsuka Shanghai Research Institute, Shanghai, China.
Abudusaimi MamutiOtsuka Shanghai Research Institute, Shanghai, China.
Fangguo YeOtsuka Shanghai Research Institute, Shanghai, China.
Jiangqin SunOtsuka Shanghai Research Institute, Shanghai, China.
Kinue OhguroInfectious Diseases Unit, Department of Medical Innovations, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
Hisashi MiyamotoMedicinal Chemistry Research Laboratories, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
Yukitaka UematsuMedicinal Chemistry Research Laboratories, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
Katsuya InagakiInfectious Diseases Unit, Department of Medical Innovations, New Drug Research Division, Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan Oka.Disuke@otsuka.jp Inagaki.Katsuya@otsuka.jp.ORCID 0000-0003-4998-6360
Jie-Fei ChengOtsuka Shanghai Research Institute, Shanghai, China.
Makoto MatsumotoPharmaceutical Business Division, Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.
Otsuka (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

OPS-2071 is a novel quinolone antibacterial agent characterized by low oral absorption that reduces the risk of adverse events typical of fluoroquinolone class antibiotics. The

Indexed as

Clostridioides difficileClostridium InfectionsQuinolonesAminoglycosidesAnimalsAnti-Bacterial AgentsClostridioidesMicrobial Sensitivity TestsRatsAminoglycosidesAnti-Bacterial AgentsQuinolonesanti-Clostridioides difficile agentnew quinoloneOPS-2071

Identifiers

PMID33495229
PMCPMC8097418
OpenAlexW3123407245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.